During the recent session, Achilles Therapeutics Plc ADR (NASDAQ:ACHL)’s traded shares were 26.07 million, with the beta value of the company hitting 1.30. At the last check today, the stock’s price was $0.94, reflecting an intraday gain of 32.69% or $0.23. The 52-week high for the ACHL share is $1.76, that puts it down -87.23 from that peak though still a striking 32.98% gain since the share price plummeted to a 52-week low of $0.63. The company’s market capitalization is $38.71M, and the average intraday trading volume over the past 10 days was 50790.0 shares, and the average trade volume was 44.26K shares over the past three months.
Achilles Therapeutics Plc ADR (ACHL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 3.50. ACHL has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.4.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Achilles Therapeutics Plc ADR (NASDAQ:ACHL) trade information
Achilles Therapeutics Plc ADR (ACHL) registered a 32.69% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 32.69% in intraday trading to $0.94, hitting a weekly high. The stock’s 5-day price performance is 32.69%, and it has moved by 27.83% in 30 days. Based on these gigs, the overall price performance for the year is 9.03%. The short interest in Achilles Therapeutics Plc ADR (NASDAQ:ACHL) is 3888.0 shares and it means that shorts have 0.1 day(s) to cover.
The consensus price target of analysts on Wall Street is $2, which implies an increase of 53.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $2 respectively. As a result, ACHL is trading at a discount of -112.77% off the target high and -112.77% off the low.
Achilles Therapeutics Plc ADR (ACHL) estimates and forecasts
Statistics show that Achilles Therapeutics Plc ADR has outperformed its competitors in share price, compared to the industry in which it operates. Achilles Therapeutics Plc ADR (ACHL) shares have gone down -26.97% during the last six months, with a year-to-date growth rate more than the industry average at 31.61% against 17.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 4.80% this quarter and then jump 13.00% in the quarter after that.
While earnings are projected to return 49.71% in 2024.
ACHL Dividends
Achilles Therapeutics Plc ADR is due to release its next quarterly earnings on 2024-Nov-11. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 2.39 million shares, is of FCPM III SERVICES B.V.’s that is approximately 5.9334% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.95 million.
